Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer
07 Agosto 2023 - 8:30AM
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage
precision oncology company focused on the treatment and prevention
of virus-associated cancers that impact patients worldwide, today
announced the appointment of Darrel P. Cohen, M.D., Ph.D. as Chief
Medical Officer (CMO), effective immediately. Dr. Cohen brings more
than 25 years of global clinical research and drug development
experience, having contributed to the successful regulatory
submissions of multiple novel oncology therapies including SUTENT®
(sunitinib), XALKORI® (crizotinib), and IBRANCE® (palbociclib). Dr.
Cohen will oversee the clinical development and regulatory
advancement of Nana-val in Epstein-Barr virus (EBV)-associated
malignances, contribute to the strategic expansion of Viracta’s
pipeline, and serve on the Executive Leadership Team.
“Darrel is a highly accomplished physician and
biopharmaceutical executive with an extraordinary depth of global
clinical development and regulatory experience in both solid tumors
and hematologic malignancies, having contributed to the approvals
of multiple therapies across various oncology indications,” said
Mark Rothera, President and Chief Executive Officer of Viracta. “We
are thrilled with the recent advancement of Nana-val in our pivotal
NAVAL-1 lymphoma trial and our progress in the Phase 1b/2 trial in
EBV-positive solid tumors. Darrel’s track record makes him an ideal
fit for Viracta at this critical inflection point as we look to
accelerate our efforts to bring Nana-val to regulatory approval and
further develop our pipeline so we can bring much-needed treatment
options to patients.”
“I am excited to be joining the Viracta team
during such an important period in the Company’s development,” said
Dr. Cohen. “The growing clinical data underscores the potential of
Viracta’s innovative ‘Kick and Kill’ approach to effectively
address the unmet treatment needs for patients with EBV-associated
cancers, with early clinical trial results supporting Nana-val's
favorable benefit/risk profile in heavily pre-treated patients. I
look forward to applying my expertise and working closely with the
entire team to reach our goal of rapidly advancing Nana-val to its
next phase of development, and ultimately realizing the full
potential of Nana-val in important indications of high unmet
medical need.”
Dr. Cohen is a hematologist/oncologist with more
than 25 years of oncology clinical research and drug development
experience. Most recently, Dr. Cohen was CMO of Cell Therapy at
Athenex Inc., where he led clinical development, clinical
operations, and regulatory affairs for its CAR-NKT cell therapy
platform and was instrumental in accelerating clinical development
plans for investigational products, KUR-501 and KUR-502. Prior to
this, Dr. Cohen was CMO at Biosight Pharmaceuticals and Head of
Clinical Development at EUSA Pharma. He has held leadership
positions of increasing responsibility at Pharmacia,
Sanofi-Aventis, and Pfizer, including Vice President of Late-Phase
Clinical Development at Pfizer Oncology where he was involved in
multiple successful regulatory submissions of new targeted cancer
drugs such as SUTENT, XALKORI, and IBRANCE. Dr. Cohen received his
M.D. and Ph.D. degrees in Medicine and Microbiology from Boston
University School of Medicine, trained as a resident in Internal
Medicine at Georgetown University Medical Center, and completed a
fellowship in hematology/oncology at Duke University Medical
Center.
About Viracta Therapeutics,
Inc.Viracta is a clinical-stage precision oncology company
focused on the treatment and prevention of virus-associated cancers
that impact patients worldwide. Viracta’s lead product candidate is
an all-oral combination therapy of its proprietary investigational
drug, nanatinostat, and the antiviral agent valganciclovir
(collectively referred to as Nana-val). Nana-val is currently being
evaluated in multiple ongoing clinical trials, including a pivotal,
global, multicenter, open-label Phase 2 basket trial for the
treatment of multiple subtypes of relapsed or refractory
Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a
multinational, open-label Phase 1b/2 trial for the treatment of
recurrent or metastatic EBV+ nasopharyngeal carcinoma and other
advanced EBV+ solid tumors. Viracta is also pursuing the
application of its “Kick and Kill” approach in other virus-related
cancers.
For additional information, please visit
www.viracta.com.
Forward-Looking StatementsThis communication
contains "forward-looking" statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including,
without limitation, statements regarding: the details, timeline and
expected progress for Viracta's ongoing and anticipated trials and
updates regarding the same. Risks and uncertainties related to
Viracta that may cause actual results to differ materially from
those expressed or implied in any forward-looking statement
include, but are not limited to: Viracta's ability to successfully
enroll patients in and complete its ongoing and planned clinical
trials; Viracta's plans to develop and commercialize its product
candidates, including all oral combinations of nanatinostat and
valganciclovir; the timing of initiation of Viracta's planned
clinical trials; the timing of the availability of data from
Viracta's clinical trials; previous preclinical and clinical
results may not be predictive of future clinical results; the
timing of any planned investigational new drug application or new
drug application; Viracta's plans to research, develop and
commercialize its current and future product candidates; the
clinical utility, potential benefits and market acceptance of
Viracta's product candidates; Viracta's ability to manufacture or
supplying nanatinostat, valganciclovir and pembrolizumab for
clinical testing.
These risks and uncertainties may be amplified
by a resurgence of the COVID-19 pandemic, or by the emergence of
another public health emergency/pandemic. If any of these risks
materialize or underlying assumptions prove incorrect, actual
results could differ materially from the results implied by these
forward-looking statements. Additional risks and uncertainties that
could cause actual outcomes and results to differ materially from
those contemplated by the forward-looking statements are included
under the caption "Risk Factors" and elsewhere in Viracta's reports
and other documents that Viracta has filed, or will file, with the
SEC from time to time and available at www.sec.gov.
The forward-looking statements included in this
communication are made only as of the date hereof. Viracta assumes
no obligation and does not intend to update these forward-looking
statements, except as required by law or applicable regulation.
Investor Relations Contact:Ashleigh BarretoHead
of Investor Relations & Corporate CommunicationsViracta
Therapeutics, Inc.abarreto@viracta.com
Media Contact:Kathy VincentGreig
Communicationskathy@greigcommunications.com
SOURCE Viracta Therapeutics, Inc.
Viracta Therapeutics (NASDAQ:VIRX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Viracta Therapeutics (NASDAQ:VIRX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024